Early access
Sign in
Taking people in PortugalPhase 3

Tests two chemotherapy plans for early stage Hodgkin lymphoma

Compares standard ABVD chemotherapy with A2VD, adding brentuximab vedotin, in early Hodgkin lymphoma.

Key facts

Who runs it
University College, London
Where
Lisbon, PortugalSee the siteAlso in 11 other countries, 71 sites
Registry title
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
Status
Recruiting
Phase
Phase 3
People taking part
1,042 people, planned
Started
14 Apr 2022
Expected to end
Sept 2032
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Involved site radiotherapy
  • Doxorubicin
  • Bleomycin
  • Brentuximab vedotin
  • Vinblastine
  • Dacarbazine
  • Haematopoietic growth factor
Record updated
8 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults and older teens with newly diagnosed early-stage classical Hodgkin lymphoma who have not had any treatment for it.

Age
16 to 69 years (18 to 69 in the US and EU).
Sex
Men and women can join.
Disease stage
Classical Hodgkin lymphoma, stage I or II, above the diaphragm, with no large (bulky) disease in the chest and no B symptoms.
Earlier treatment
No earlier treatment for Hodgkin lymphoma, except short courses of oral steroids (up to 7 days).
Biomarker or test result
Disease that shows up on the starting PET scan (FDG-avid lesions).

Main reasons for not taking part

  • Disease below the diaphragm
  • Nodular lymphocyte predominant Hodgkin lymphoma
  • Another cancer in the last 5 years (some skin and in situ cancers are allowed)
  • HIV, hepatitis C or active hepatitis B infection
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 30 criteriaShow less

Who can take part

  • Males and females aged 16-69 years (inclusive) (age range is 18-69 in US and EU)
  • Histologically confirmed classical Hodgkin lymphoma
  • Stage I or II supradiaphragmatic disease with no mediastinal bulk disease (defined as greater than a third of the transthoracic diameter at any level of thoracic vertebra as determined by CT) or B symptoms. Bulky disease at other sites is acceptable. Extranodal disease (single extranodal site (stage I) or contiguous nodal extension (stage II)) is acceptable
  • ECOG performance status 0-2
  • No previous treatment for Hodgkin lymphoma
  • Fit to receive anthracycline-based chemotherapy (patients with a history of ischaemic heart disease or hypertension should have a left ventricular ejection fraction of ≥50%)
  • Creatinine clearance (measured or calculated >40ml/min
  • Total bilirubin <1.5 x upper limit of normal, unless attributable to disease or known Gilbert's syndrome
  • ALT or AST < 2 x upper limit of normal
  • Adequate bone marrow function with neutrophils ≥1.0x10\^9/l and platelets ≥100x10\^9/l
  • Haemoglobin ≥8g/dL
  • Willing and able to comply with the requirements of the protocol, including contraceptive advice, where applicable
  • Written informed consent

Who cannot take part

  • Previous treatment for Hodgkin lymphoma, excluding short courses of oral corticosteroids at a dose of 100mg prednisolone (or equivalent) for up to 7 days
  • Any active systemic viral, bacterial or fungal infection requiring systemic antibiotics, antivirals or antifungals within 2 weeks prior to first trial drug dose
  • Receiving or recently treated with any other investigational agent (within 4 weeks of trial entry)
  • Infradiaphragmatic disease
  • Other cancer diagnosed with the last 5 years. Patients with completely excised carcinoma in situ of any type and basal or squamous cell carcinoma of the skin are not excluded
  • Recurrent or persistent other cancer within last 5 years irrespective of date of initial diagnosis
  • History of or current progressive multi-focal leukoencephalopathy or other chronic condition of the brain
  • Symptomatic neurologic disease compromising normal activities of daily living or requiring medications
  • Infection with HIV, hepatitis C or active hepatitis B infection (surface antigen or DNA positive)
  • Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin or any component of ABVD
  • Known history of any cardiovascular or respiratory conditions that would preclude anthracycline or bleomycin administration
  • Other significant medical or psychiatric comorbidity that in the opinion of the investigator would make administration of ABVD or A2VD hazardous
  • Nodular lymphocyte predominant Hodgkin lymphoma
  • Age 70 years or over or age 15 years or under
  • Absence of FDG-avid lesions on baseline PET scan
  • Pre-existing grade ≥1 sensory or motor neuropathy from any cause
  • Pregnant or breastfeeding women

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 16 and 69 years old?

Where in Portugal

Also in 11 other countries, 71 sites

  • Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E.Lisbon, PortugalTaking people

About the trial

What the trial wants to find out

RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will be combined to achieve the total sample size. Data analysis will be performed by UCL and therefore UCL is responsible for the clinicaltrials.gov entry.

Read full original descriptionShow less

Eligible patients will be randomised to receive either ABVD or A2VD chemotherapy.

An interim PET-CT scan will be performed after 2 cycles of treatment, which will be used to adapt subsequent treatment. Patients will receive a total of 3-4 cycles of chemotherapy and may also receive involved site radiotherapy as consolidation.

Patients will be followed up for a minimum of 5 years after treatment.

The 2 groups in the trial

  • ABVD +/- ISRTExisting treatment, for comparison

    2 x 28 day cycles of ABVD: Doxorubicin 25mg/m\^2 IV days 1 \& 15 Bleomycin 10000 IU/m\^2 days 1 \& 15 Vinblastine 6mg/m\^2 days 1 \& 15 Dacarbazine 375mg/m\^2 days 1 \& 15 PET-CT after 2 cycles will determine subsequent treatment: Deauville score 1-3 (PET CMR): 1 further cycle of ABVD then follow up Deauville score 4 (PET positive): 2 further cycles of ABVD followed by involved site radiotherapy (ISRT) Deauville score 5: withdraw from trial treatment; further treatment will be given at the treating clinician's discretion. Enter follow up for the trial.

    Treatment: Involved site radiotherapy, Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine

  • A2VD +/- ISRTTreatment being tested

    2 x 28 day cycles of A2VD: Doxorubicin 25mg/m\^2 IV days 1 \& 15 Brentuximab vedotin 1.2mg/kg (max 120mg) days 1 \& 15 Vinblastine 6mg/m\^2 days 1 \& 15 Dacarbazine 375mg/m\^2 days 1 \& 15 Filgrastim (or equivalent haematopoietic growth factor) for 5-7 days from day 2 and day 16 (or single dose of peg-filgrastim on days 2 \& 16) PET-CT after 2 cycles will determine subsequent treatment: Deauville score 1-3 (PET CMR): 1 further cycle of A2VD then follow up Deauville score 4 (PET positive): 2 further cycles of A2VD followed by involved site radiotherapy (ISRT) Deauville score 5: withdraw from trial treatment; further treatment will be given at the treating clinician's discretion. Enter follow up for the trial.

    Treatment: Involved site radiotherapy, Doxorubicin, Brentuximab vedotin, Vinblastine, Dacarbazine, and Haematopoietic growth factor

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma
Plain-language title
Tests two chemotherapy plans for early stage Hodgkin lymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT04685616, who can take part
Record updated
8 July 2026